Chemically programmed bispecific antibodies that recruit and activate T cells

Journal of Biological Chemistry

Volumn 287, Issue 34, 2012, Pages 28206-28214

  Cui, Huiting ^a   Thomas, Joshua D ^b   Burke, Terrence R ^b   Rader, Christoph ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C (PROGRAMMING LANGUAGE); CELL CULTURE; CYTOTOXICITY; T-CELLS; TUMORS;

ANTIBODY THERAPEUTICS; ANTIBODY-FRAGMENT; CELL-BE; CELL/B.E; CELL/BE; CYTOTOXIC; HUMANIZED ANTIBODY; IMMUNE CELLS; SIMULTANEOUS BINDINGS; TUMOUR CELLS;

ANTIBODIES;

BIOTIN; BISPECIFIC ANTIBODY; CD69 ANTIGEN; FOLATE RECEPTOR 1; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; SELENOCYSTEINE; VERY LATE ACTIVATION ANTIGEN 4;

ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CD3+ T LYMPHOCYTE; CELL ADHESION; CELL INTERACTION; CELL SPECIFICITY; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; HELA CELL; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY TUMOR; PRIORITY JOURNAL; SUPERNATANT; T LYMPHOCYTE ACTIVATION;

EID: 84865235085     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.384594     Document Type: Article

References (33)

1. Carter, P. (2001) Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129
2. Li, J., and Zhu, Z. (2010) Research and development of next generation of antibody-based therapeutics. Acta Pharmacol. Sin. 31, 1198-1207
3. Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C. T., and Sampson, J. H. (2011) Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin. Biol. Ther. 11, 843-853
4. Holmes, D. (2011) Buy buy bispecific antibodies. Nat. Rev. Drug Discov. 10, 798-800
5. Chames, P., and Baty, D. (2009) Bispecific antibodies for cancer therapy. The light at the end of the tunnel? mAbs 1, 539-547
6. Anderson, P. M., Crist, W., Hasz, D., Carroll, A. J., Myers, D. E., and Uckun, F. M. (1992) G19.4(alpha CD3) x B43(α CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 80, 2826-2834
7. Baeuerle, P. A., and Reinhardt, C. (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941-4944
8. Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., Shah, K., Jin, L., Zhang, S., He, L., Zhang, T., Ciccarone, V., Koenig, S., Bonvini, E., and Johnson, S. (2011) Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117, 4542-4551
9. Rader, C. (2011) DARTs take aim at BiTEs. Blood 117, 4403-4404
10. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmüller, G., Reinhardt, C., Baeuerle, P. A., and Kufer, P. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977
11. Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H. A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Köhne-Volland, R., Brüggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P. A., Kneba, M., Einsele, H., Riethmüller, G., Hoelzer, D., Zugmaier, G., and Bargou, R. C. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498
12. Löfblom, J., Frejd, F. Y., and Ståhl, S. (2011) Non-immunoglobulin-based protein scaffolds. Curr. Opin. Biotechnol. 22, 843-848
13. Kodadek, T. (2010) Synthetic receptors with antibody-like binding affinities. Curr. Opin. Chem. Biol. 14, 713-720
14. Bernardo, P. H., and Tong, J. C. (2012) In silico design of small molecules. Methods Mol. Biol. 800, 25-31
15. Rader, C., Sinha, S. C., Popkov, M., Lerner, R. A., and Barbas, C. F., 3rd. (2003) Chemically programmed monoclonal antibodies for cancer therapy. Adaptor immunotherapy based on a covalent antibody catalyst. Proc. Natl. Acad. Sci. U.S.A. 100, 5396-5400 (Pubitemid 36542716)
16. Hofer, T., Thomas, J. D., Burke, T. R., Jr., and Rader, C. (2008) An engineered selenocysteine defines a unique class of antibody derivatives. Proc. Natl. Acad. Sci. U.S.A. 105, 12451-12456
17. Gavrilyuk, J. I., Wuellner, U., Salahuddin, S., Goswami, R. K., Sinha, S. C., and Barbas, C. F., 3rd. (2009) An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg. Med. Chem. Lett. 19, 3716-3720
18. Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N. J., Shields, M. J., Parish, M., Murphy, R. E., Del Rosario, J., Oates, B. D., Lai, J. Y., Matin, M. J., Ainekulu, Z., Bhat, A., Bradshaw, C. W., Woodnutt, G., Lerner, R. A., and Lappe, R. W. (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U.S.A. 107, 22611-22616
19. Woodnutt, G., Violand, B., and North, M. (2008) Advances in protein therapeutics. Curr. Opin. Drug Discov. Devel. 11, 754-761
20. Hofer, T., Skeffington, L. R., Chapman, C. M., and Rader, C. (2009) Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 48, 12047-12057
21. Imai, Y., Shimaoka, M., and Kurokawa, M. (2010) Essential roles of VLA-4 in the hematopoietic system. Int. J. Hematol. 91, 569-575
22. Kurtova, A. V., Tamayo, A. T., Ford, R. J., and Burger, J. A. (2009) Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d). Importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604-4613
23. Peng, L., Liu, R., Marik, J., Wang, X., Takada, Y., and Lam, K. S. (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat. Chem. Biol. 2, 381-389 (Pubitemid 43936939)
24. Denardo, S. J., Liu, R., Albrecht, H., Natarajan, A., Sutcliffe, J. L., Anderson, C., Peng, L., Ferdani, R., Cherry, S. R., and Lam, K. S. (2009) 111In-LLP2A-DOTA polyethylene glycol-targeting α4β1 integrin. Comparative pharmacokinetics for imaging and therapy of lymphoid malignancies. J. Nucl. Med. 50, 625-634
25. Thomas, J. D., Hofer, T., Rader, C., and Burke, T. R., Jr. (2008) Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. Bioorg. Med. Chem. Lett. 18, 5785-5788
26. Spannuth, W. A., Sood, A. K., and Coleman, R. L. (2010) Farletuzumab in epithelial ovarian carcinoma. Expert Opin. Biol. Ther. 10, 431-437
27. Low, P. S., and Kularatne, S. A. (2009) Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 13, 256-262
28. Antony, A., Tang, Y. S., Khan, R. A., Biju, M. P., Xiao, X., Li, Q. J., Sun, X. L., Jayaram, H. N., and Stabler, S. P. (2004) Translational up-regulation of folate receptors is mediated by homocysteine via RNA-heterogeneous nuclear ribonucleoprotein E1 interactions. J. Clin. Invest. 113, 285-301 (Pubitemid 38544213)
29. Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beverley, P. C., Feldmann, M., and Carter, P. (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175, 217-225
30. Zhu, Z., and Carter, P. (1995) Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J. Immunol. 155, 1903-1910
31. Liu, M. A., Nussbaum, S. R., and Eisen, H. N. (1988) Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells. Science 239, 395-398 (Pubitemid 18062671)
32. Kranz, D. M., Patrick, T. A., Brigle, K. E., Spinella, M. J., and Roy, E. J. (1995) Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. U.S.A. 92, 9057-9061
33. Rund, L. A., Cho, B. K., Manning, T. C., Holler, P. D., Roy, E. J., and Kranz, D. M. (1999) Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer 83, 141-149 (Pubitemid 29409490)